HOME >> BIOLOGY >> NEWS
Clinical trial data regarding NKTR-061 will be presented at ATS International Conference

San Francisco, Calif. -- Results of a Phase 2a clinical trial evaluating the potential of NKTR-061 (inhaled amikacin) to treat hospital acquired gram-negative bacterial pneumonia will be presented at the American Thoracic Society (ATS) International Conference, May 18 23, 2007, in San Francisco.

WHO: Dr. Michael S. Niederman, MD, Chairman, Department of Medicine, Winthrop-University Hospital, Professor of Medicine; Vice Chairman, Department of Medicine, SUNY at Mineoloa.

Dr. Jean Chastre, Professor of Medicine, University of Paris.

WHAT: Four posters detailing the results of a Phase 2a clinical trial evaluating the pharmacokinetic, serum and tracheal aspirate concentration, safety and antibiotic reduction properties of NKTR-061.

Data will be presented and discussed at this ATS session to show a reduction in the use of IV antibiotics in mechanically ventilated patients during treatment of gram-negative pneumonia with NKTR-061. Further, the data indicate that the administration of NKTR-061 resulted in high tracheal aspirate concentrations and high epithelial lining fluid concentrations of amikacin in gram-negative pneumonia in intubated mechanically ventilated patients. Finally, data will be presented indicating that NKTR-061 achieves safe serum concentrations following multiple dosing in intubated mechanically ventilated patients with gram-negative pneumonia.

WHEN: Monday, May 21st, 2007, 8:15-11:00 am (PT)

WHERE: The American Thoracic Society (ATS) International Conference at the San Francisco Marriott Hotel.

ABOUT NKTR-061:

NKTR-061 (inhaled amikacin) is being tested to evaluate the safety and tolerability of amikacin formulated for inhalation for the adjunctive treatment of gram-negative pneumonia in ventilated patients diagnosed with hospital or ventilator associated pneumonia. This new inhaled antibiotics product candidate leverages N
'"/>

Contact: Tim Warner
twarner@nektar.com
650-283-4915
Nektar Therapeutics
9-May-2007


Page: 1 2

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial for diabetic macular edema
4. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
5. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
6. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
7. October MCP: A special issue on Clinical Proteomics
8. Columbia University Medical Center receives major new NIH Clinical Science investment funds
9. Researchers reverse juvenile diabetes in animal model; Clinical trial FDA approved
10. Clinical trial to test stem cell approach for children with brain injury
11. Vaccine trials inject hope into koalas future

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... ... July 01, 2020 , ... ... had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in ... Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... instrumentation, is pleased to announce the next event in a series of TOPIQ ... , The TOPIQ series of webinars was developed in response to social distancing ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 30, 2020 , ... ... data insights, today announced that the launch of a new clinical ... data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service ...
(Date:6/28/2020)... ... June 25, 2020 , ... With ... a vaccine or drug treatment. In an effort to better understand the cellular ... the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved ...
(Date:6/28/2020)... ... 26, 2020 , ... The Security Industry Association ... opposition to the recently introduced bicameral Facial Recognition and Biometric Technology Moratorium ... use of nearly all biometric and related image analytics technologies, incorrectly labeling all ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... indoor environments, announced today that Derek Fournier has been appointed CEO and President. ... the Board, effective immediately. , “DeCurtis Corporation has been on an incredible ...
Breaking Biology Technology:
Cached News: